Instrument Inactif

Autres langues Sigyn Therapeutics, Inc. Other OTC

Actions

SIGY

US82674U1060

Equipement, fournitures et distribution médicale

Autres langues

07/05	Oragenics signs letter of intent to license Cardiodialysis(TM) technology from Sigyn Therapeutics to target TBI-induced systemic inflammation
07/05	Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
07/05	Oragenics Signs Letter of Intent to License CardioDialysis? Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
02/04	Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE
24/03	Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases
14/03	Sigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale Initiatives
12/02	Sigyn Therapeutics, Inc. announced that it has received $0.04 million in funding from Brio Capital L.P., Osher Capital Partners, LLC
15/01	Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives
08/01	The Emergence of Blood Purification Devices to Treat Cardiovascular Disease
11/12	Sigyn CEO Note: First-In-Industry Attributes of CardioDialysisTM to Treat Cardiovascular Disease
03/12	Sigyn CEO Note: Nature Publication Reinforces Rationale for CardioDialysisTM to Address Cardiovascular Disease in Dialysis Patients
18/11	Sigyn CardioDialysis(TM) Featured on the Big Biz Show
14/11	Sigyn Therapeutics Reports Third Quarter Financial Results and Subsequent Introduction of CardioDialysis(TM)
14/11	Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
07/11	Sigyn Therapeutics Releases Shareholder Letter to Introduce CardioDialysis(TM)
21/10/25	Sigyn Therapeutics, Inc. to Present at the LD Micro Main Event XIX
17/10/25	Sigyn Therapeutics, Inc. to Present at the LD Micro Main Event XIX
16/09/25	Sigyn Therapeutics to Present at the Life Sciences Virtual Investor Forum on September 18th
11/09/25	Sigyn Therapeutics Appoints Dr. Christoph Zaba to Its Scientific Advisory Board
05/09/25	Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
03/09/25	Sigyn Therapeutics Announces Cardiovascular Disease Study
15/08/25	Sigyn Therapeutics, Inc. Announces Director Resignations
08/08/25	Sigyn Therapeutics, Inc. announced that it expects to receive $0.5 million in funding
20/05/25	Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025
15/04/25	Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024